Milk antibody response after 3 rd COVID-19 vaccine and SARS-CoV-2 infection and implications for infant protection
iScience, ISSN: 2589-0042, Vol: 26, Issue: 10, Page: 107767
2023
- 6Citations
- 16Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations6
- Citation Indexes6
- CrossRef4
- Captures16
- Readers16
- 16
Article Description
Little is known about the persistence of human milk anti-SARS-CoV-2 antibodies after 2 nd and 3 rd vaccine doses and infection following 3 rd dose. In this study, human milk, saliva, and blood samples were collected from 33 lactating individuals before and after vaccination and infection. Antibody levels were measured using ELISA and symptoms were assessed using questionnaires. We found that after vaccination, milk anti-SARS-CoV-2 antibodies persisted for up to 8 months. In addition, distinct patterns of human milk IgA and IgG production and higher milk RBD-blocking activity was observed after infection compared to 3-dose vaccination. Infected mothers reported more symptoms than vaccinated mothers. We examined the persistence of milk antibodies in infant saliva after breastfeeding and found that IgA was more abundant compared to IgG. Our results emphasize the importance of improving the secretion of IgA antibodies to human milk after vaccination to improve the protection of breastfeeding infants.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S2589004223018448; http://dx.doi.org/10.1016/j.isci.2023.107767; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85170406928&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37731614; https://linkinghub.elsevier.com/retrieve/pii/S2589004223018448; https://dx.doi.org/10.1016/j.isci.2023.107767
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know